Bill

HRES 172

Raising awareness for the sarcoma cancer chordoma.

119th Congress Introduced by Hank Johnson and 4 co-sponsors

The bill urges increased funding and support for faster diagnosis, new treatments, smoother research-to-treatment transitions, and patient-centered drug discovery for chordoma.

Referred to the House Committee on Energy and Commerce.

WeVote Research Nonpartisan

Bill Summary · HRES 172

Summary of HRES 172: Raising awareness for the sarcoma cancer chordoma

Overview

Bill Number: HRES 172
Title: Raising awareness for the sarcoma cancer chordoma
Type: House Resolution (non-binding)
Purpose: Expresses the sense of the House that chordoma patients and families need increased funding and support in key areas related to diagnosis, treatment development, research-to-treatment transitions, and patient-centered drug discovery.
Status: Referred to the House Committee on Energy and Commerce
Introduced: February 27, 2025

What the bill does

This is a non-binding resolution that does not create new law or authorize new spending. Instead, it signals the sense of the House regarding priorities for chordoma-related issues and directs attention to specific needs.

Key provisions (as introduced)

The resolution states that chordoma patients and families need increased funding and support for four areas:
1. Accurate and early diagnosis
2. Development of new treatments, diagnostics, and cures
3. Fewer hurdles between research and new treatments
4. Patient-centric approaches to drug discovery and development

Who is affected

Chordoma patients and families: Primary beneficiaries through heightened attention to diagnosis, treatment options, and research efforts.
Researchers and medical developers: Encouraged focus on faster translation from research to treatments and on patient-centered drug discovery.
Federal entities (informational/advocacy impact): Agencies like the NIH/NCI and other researchers and stakeholders may be encouraged to pursue chordoma-focused initiatives in line with the resolution’s sense of priority; no specific mandates or funding authorizations are included in the text provided.

Procedural and timeline notes

Introduced on February 27, 2025.
Referred to the House Committee on Energy and Commerce for consideration. No further actions are listed in the provided information.

Potential impact and context

As a non-binding resolution, HRES 172 primarily serves to raise awareness and articulate congressional priorities.
It could influence future legislative or appropriations discussions by highlighting chordoma as a area needing attention and by signaling support for related initiatives in diagnosis, research, and patient-centered care.
The resolution could help mobilize patients, clinicians, researchers, and advocacy groups to advocate for funding and programmatic efforts aligned with the four areas identified.

Compiled from official sources — confirm details with the bill’s official record.